OPVIVO Qvantig launch

The pioneering immuno-oncology treatment OPDIVO expanded its portfolio with the introduction of an option with subcutaneous administration. While the story to be told was simple, the launch was relentless sprint and a heavy lift. Developed full menu of tactics for both HCP and clinical nurse teams available for use on Day 1.

Screenshot 2025-03-04 at 11.10.55 AM.png
Screenshot 2025-03-04 at 11.13.26 AM.png
Screenshot 2025-03-04 at 11.10.00 AM.png
Screenshot 2025-03-04 at 11.10.20 AM.png
Screenshot 2025-03-04 at 12.51.23 PM.png